- Home
- OPBK vs MDXH Comparison
OPBK vs MDXH Comparison
Compare OPBK & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | OPBK | MDXH |
|---|---|---|
| Founded | 2005 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.5M | 183.4M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | OPBK | MDXH |
|---|---|---|
| Price | $13.92 | $3.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $16.50 | $7.67 |
| AVG Volume (30 Days) | 36.6K | ★ 138.8K |
| Earning Date | 01-22-2026 | 02-26-2026 |
| Dividend Yield | ★ 3.43% | N/A |
| EPS Growth | ★ 23.74 | N/A |
| EPS | ★ 1.72 | N/A |
| Revenue | $91,100,000.00 | ★ $103,069,000.00 |
| Revenue This Year | $15.80 | $23.34 |
| Revenue Next Year | $10.12 | $22.98 |
| P/E Ratio | $8.15 | ★ N/A |
| Revenue Growth | 14.91 | ★ 21.68 |
| 52 Week Low | $10.43 | $1.35 |
| 52 Week High | $15.27 | $5.33 |
Technical Indicators
Market Signals| Indicator | OPBK | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 45.53 | 50.26 |
| Support Level | $14.12 | $3.45 |
| Resistance Level | $14.43 | $3.80 |
| Average True Range (ATR) | 0.40 | 0.22 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 39.60 | 24.68 |
Price Performance
Historical ComparisonAbout OPBK OP Bancorp
OP Bancorp is engaged in the general commercial banking business in Los Angeles, Orange, and Santa Clara Counties, California, Carrollton, Texas, and Las Vegas, Nevada. The Bank is focused on serving the banking needs of small- and medium-sized businesses, professionals, and residents with a particular emphasis on Korean and other ethnic minority communities. It operates with eleven full branches.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.